BNF May 2022 Update

This update contains 6 significant changes, 1 dose change, 1 new monograph, and 1 new preparation.

Significant Changes:

• Amiodarone hydrochloride (Cordarone X®): reminder of risks of treatment and need for patient monitoring and supervision [MHRA/CHM advice].
• Cladribine (Mavenclad®): new advice to minimise risk of serious liver injury [MHRA/CHM advice].
• COVID-19: updated guidance.
• Glaucoma and ocular hypertension: updated guidance on management
• Metformin hydrochloride: study shows no safety concerns in pregnancy [MHRA/CHM advice].
• Potassium permanganate: inadvertent oral administration of potassium permanganate [National Patient Safety Alert advice].

Dose Changes:

• Remdesivir [update to indications and dosing including removal of body-weight from dose statement].

New Monographs:

• Aspaveli® [pegcetacoplan]

New Preparations: Nephrotrans® [sodium bicarbonate]

For further details on changes in the BNF click on https://www.medicinescomplete.com/#/content/bnf/PHP107699